Arbutus Biopharma has made a statement regarding the patent dispute ruling by the U.S. District Court for the District of Delaware. The lawsuit, initiated by Arbutus and its licensing partner, Genevant Sciences, targets Moderna with the accusation of patent infringement in their production and sale of the Covid-19 vaccine, MRNA-1273. As the alleged owners of the patented lipid nanoparticle (LNP) technology used by Moderna, Arbutus and Genevant are seeking just compensation.
The Court has concurred with the plaintiff's argument that the specified molar percentage ranges could apply to any particle, without limiting to finished particles that are not subjected to further process stages.
"We are satisfied with how the Court interpreted the controversial claim terms", commented Michael McElhaugh, who is currently serving as the Interim President and CEO of Arbutus Biopharma.
For more articles about health news, you are welcome to visit our website at rttnews.com.
